Us Bancorp \De\ Immuno Gen, Inc. Transaction History

Us Bancorp \De\

$77.3 Billion
Q3 2024

19 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 09, 2024	SELL	$12.46 - $29.95 $516,940 - $1.24 Million	-41,488 Reduced 98.86%	479 $14,000
Q3 2023 Nov 03, 2023	BUY	$14.09 - $19.87 $25,756 - $36,322	1,828 Added 4.55%	41,967 $666,000
Q2 2023 Aug 09, 2023	BUY	$3.75 - $20.05 $149,670 - $800,235	39,912 Added 17582.38%	40,139 $757,000
Q4 2022 Feb 13, 2023	BUY	$4.55 - $6.31 $1,032 - $1,432	227 New	227 $1,000
Q1 2022 May 11, 2022	SELL	$4.26 - $7.48 $144 - $254	-34 Closed	0 $0
Q4 2021 Feb 11, 2022	SELL	$4.75 - $7.5 $2,246 - $3,547	-473 Reduced 93.29%	34 $0
Q3 2021 Nov 10, 2021	BUY	$5.02 - $6.59 $170 - $224	34 Added 7.19%	507 $3,000
Q2 2021 Aug 05, 2021	SELL	$5.79 - $8.6 $1,175 - $1,745	-203 Reduced 30.03%	473 $3,000
Q1 2021 Apr 28, 2021	BUY	$6.5 - $10.53 $1,319 - $2,137	203 Added 42.92%	676 $5,000
Q4 2020 Feb 04, 2021	BUY	$3.7 - $7.66 $1,750 - $3,623	473 New	473 $3,000
Q1 2020 May 13, 2020	SELL	$2.12 - $6.8 $1,248 - $4,005	-589 Closed	0 $0
Q4 2019 Feb 04, 2020	BUY	$2.25 - $5.8 $58 - $150	26 Added 4.62%	589 $3,000
Q3 2019 Nov 08, 2019	BUY	$2.22 - $3.39 $959 - $1,464	432 Added 329.77%	563 $1,000
Q2 2019 Aug 13, 2019	SELL	$1.8 - $3.3 $27,207 - $49,879	-15,115 Reduced 99.14%	131 $0
Q1 2019 May 08, 2019	SELL	$2.41 - $5.91 $313 - $768	-130 Reduced 0.85%	15,246 $42,000
Q4 2018 Feb 13, 2019	SELL	$3.94 - $9.7 $1,851 - $4,559	-470 Reduced 2.97%	15,376 $74,000
Q3 2018 Nov 01, 2018	SELL	$8.6 - $11.26 $361 - $472	-42 Reduced 0.26%	15,846 $150,000
Q1 2018 May 08, 2018	BUY	$6.7 - $12.95 $5,949 - $11,499	888 Added 5.92%	15,888 $167,000
Q3 2017 Nov 13, 2017	BUY	$5.4 - $8.47 $81,000 - $127,050	15,000	15,000 $115,000

Others Institutions Holding IMGN

# of Institutions

Shares Held

1.41M

Call Options Held

Put Options Held

View Full List

About ImmunoGen, Inc.

Ticker IMGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 220,712,992
Description
ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sun...

More about IMGN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Us Bancorp \De\, based on Form 13F filings with the SEC.

News

Stay updated on Us Bancorp \De\ with notifications on news.

Account